re: #2 dr. klys

Dark, that doesn’t address the problem.

Drug companies have no financial interest in producing new antibiotics because the research is expensive and they are generally a single-shot course of treatment: people take them once and then don’t need them again. There’s no profit to be made there by selling the drug repeatedly to a customer. Shortening the testing process doesn’t change those facts.

Reducing their testing costs was the objective I was trying to get at.